(VIANEWS) – Shares of GENTIAN DIAGNOSTIC (Oslo Børs Benchmark Index_GI: GENT.OL) jumped by a staggering 20.51% in 10 sessions from kr39 to kr47.00 at 14:37 EST on Wednesday, after five successive sessions in a row of gains. Oslo Børs Benchmark Index_GI is rising 0.35% to kr1,208.89, following the last session’s downward trend.
GENTIAN DIAGNOSTIC’s last close was kr46.90, 3.7% below its 52-week high of kr48.70.
About GENTIAN DIAGNOSTIC
Gentian Diagnostics ASA researches, develops, and produces biochemical reagents for use in medical diagnostics and research in Europe, Asia, and the United States. It offers in-vitro diagnostic reagents for clinical chemistry analyzers. The company's products include the gentian calprotectin immunoassay, a turbidimetric immunoassay used for the measurement of calprotectin in plasma and serum for detection and assessment of inflammation; Cystatin C, a superior GFR marker for the diagnosis and therapeutic control of renal function; NT-proBNP Immunoassay for diagnosis, monitoring, and assessment of severity in individuals suspected of having congestive heart failure; and Canine c-reactive protein (CRP) immunoassay, a particle-enhanced turbidimetric immunoassay for quantitative determination of canine CRP in dog plasma and serum. It also provides turbidimetric SARS-CoV-2 total antibody immunoassay, a quantitative antibody test for detecting antibodies targeting the S1-subunit. Gentian Diagnostics ASA was incorporated in 2001 and is headquartered in Moss, Norway.
Earnings Per Share
As for profitability, GENTIAN DIAGNOSTIC has a trailing twelve months EPS of kr-1.68.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -14.36%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
GENTIAN DIAGNOSTIC’s EBITDA is -103.3.
More news about GENTIAN DIAGNOSTIC (GENT.OL).
